Predictors of Loss of Asthma Control Induced by Corticosteroid Withdrawal
Authors:
Open Access
- 1 January 2006
- journal article
- clinical trial
- Published by Wiley in Canadian Respiratory Journal
- Vol. 13 (3) , 129-133
Abstract
BACKGROUND: Asthma guidelines recommend reducing the dose of inhaled corticosteroids after establishing control.OBJECTIVE: To identify predictors of loss of control and the kinetics of symptoms, and inflammatory and physiological measurements when inhaled corticosteroids are reduced in patients with stable asthma.PATIENTS AND METHODS: In a single‐blind study, the daily dose of inhaled corticosteroid was reduced by one‐half at intervals of 20±2 days in 17 adults with controlled asthma until loss of asthma control occurred or until the corticosteroid was replaced with placebo for 20 days. The patients recorded symptoms and peak expiratory flow each day, and forced expiratory volume in 1 s (FEV1), the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20), exhaled nitric oxide, and eosinophils in sputum and blood were measured every 10 days. A loss of asthma control was defined as a worsening of the symptoms score of at least 20%, and either a decrease in FEV1 of at least 15% or a decrease in PC20 of at least fourfold.RESULTS: Two patients had a respiratory infection and were withdrawn from the study. In eight patients, asthma became uncontrolled after a mean of 33 days (range 13 to 48 days). This was accurately reflected by a worsening of all parameters. The first parameter to change was the sputum eosinophil percentage (20 days before the loss of asthma control). Significant changes in exhaled nitric oxide, FEV1 and methacholine PC20 were observed only when the symptoms became uncontrolled. A high blood eosinophil count at baseline (risk ratio of 2.5, 95% CI 1.0 to 6.5) and an increase in sputum eosinophil count after the reduction of corticosteroids were predictors of loss of asthma control.CONCLUSION: In patients whose asthma is controlled on inhaled corticosteroid, it is prudent not to reduce the dose further if the blood eosinophils are increased or if the sputum eosinophils increase by as little as 1% after the reduction of corticosteroids.Keywords
Funding Information
- AstraZeneca Canada
- Canadian Institutes of Health Research
This publication has 18 references indexed in Scilit:
- Determining asthma treatment by monitoring sputum cell counts: effect on exacerbationsEuropean Respiratory Journal, 2006
- Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroidsJournal of Allergy and Clinical Immunology, 2005
- Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled CorticosteroidsAmerican Journal of Respiratory and Critical Care Medicine, 2001
- A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammationJournal of Allergy and Clinical Immunology, 2000
- Changes in Sputum Eosinophils Predict Loss of Asthma ControlAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Lung Function and Sputum Characteristics of Patients with Severe Asthma During an Induced Exacerbation by Double-Blind Steroid WithdrawalAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Prednisone-dependent asthma: inflammatory indices in induced sputumEuropean Respiratory Journal, 1999
- Potential Masking Effects of Salmeterol on Airway Inflammation in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Indices of Airway Inflammation in Induced Sputum: Reproducibility and Validity of Cell and Fluid-Phase MeasurementsAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Effects of Reducing or Discontinuing Inhaled Budesonide in Patients with Mild AsthmaNew England Journal of Medicine, 1994